問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of General Internal Medicine

Division of Cardiovascular Diseases

更新時間：2023-09-19

呂尚謁
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

8Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

呂尚謁

List

10Cases

2025-10-01 - 2030-06-30

Active
EASi-PROTKT™ is a phase III, double-blind, randomized, parallel-group superiority trial evaluating the efficacy and safety of oral vicadrostat (BI 690517) combined with empagliflozin compared to placebo combined with empagliflozin in participants with type 2 diabetes, hypertension, and a history of cardiovascular disease.

  • Condition/Disease

    • The time elapsed before the first occurrence of a CV death or HFE (defined as HHF or emergency HF visit). CV deaths include deaths of unknown cause.

  • Test Drug

    BI 690517 (Vicadrostat) or matching placebo Empagliflozin

Participate Sites
13Sites

Recruiting13Sites

2025-07-01 - 2030-12-31

Active

  • Condition/Disease

  • Test Drug

Participate Sites
23Sites

Recruiting23Sites

2023-10-02 - 2030-09-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2023-05-01 - 2028-07-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2023-03-01 - 2027-02-28

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
17Sites

Recruiting17Sites

2024-07-30 - 2028-09-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Not yet recruiting8Sites

Recruiting4Sites

2020-06-15 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Not yet recruiting4Sites

Recruiting8Sites

2023-12-15 - 2028-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2023-12-15 - 2028-06-30

Phase III

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

  • Condition/Disease

    Transthyretin amyloid cardiomyopathy

  • Test Drug

    ALXN2220

Participate Sites
5Sites

Recruiting5Sites

2019-08-20 - 2021-08-02

Phase I

A phase I, open label study to evaluate the safety and to explore efficacy of allogeneic umbilical cord mesenchymal stem cells in patients with ST-elevation acute myocardial infarction

  • Condition/Disease

    Acute Myocardial Infarction

  • Test Drug

    UMSC01

Participate Sites
1Sites

Recruiting1Sites

蕭連城
China Medical University Hospital

Division of Cardiovascular Diseases

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB